• Green light for Amryt's epidermolysis bullosa study pharmatimes
    January 08, 2019
    An Independent Data Monitoring Committee (IDCM) has recommended that Amryt’s pivotal Phase III EASE trial for AP101 - a potential treatment for the currently incurable Epidermolysis Bullosa (EB) - should continue.
PharmaSources Customer Service